Negative schizophrenic symptoms as prefrontal cortex dysfunction: Examination using a task measuring goal neglect

Fuentes‐Claramonte, Paola; Ramiro, Núria; Torres, Llanos; Argila-Plaza, Isabel; Salgado‐Pineda, Pilar; Soler-Vidal, Joan; Garcia, María Ángeles; Albacete, Auria; Bosque, Clara; Panicalli, Francesco; Boix, Ester; Munuera, Josep; Tristany, Josep; Sarró, Salvador; Bernardo, Miquel; Salvador, Raymond; McKenna, Peter; Pomarol‐Clotet, Edith

doi:10.1016/j.nicl.2022.103119

Cited by 9 publications

(4 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Smith et al, (2013) showings that a decrease in volume of the dorsolateral frontal cortex (DLPFC) is associated with improvement of depression symptoms in patients with depression. WM connectivity abnormalities in the superior frontal executive region have been proposed to explain negative symptoms in schizophrenia (Asami et al, 2014;Fuentes et al, 2022). In accordance with these results, a study by Dazzan and colleagues (2012), demonstrated that subjects who develop affective psychosis had reductions in the frontal cortex (Dazzan et al, 2012).…”

Section: Structural Findingsmentioning

confidence: 71%

Sex differences and symptom based gray and white matter densities in schizophrenia

Marïë¹

2022

Cortica

View full text Add to dashboard Cite

We investigated the association between densities in gray matter (GMD) and white matter (WMD) phenotypes and positive (PS) and negative (NS) symptoms in 40 schizophrenia patients (SZ). Cerebral densities were compared with 41 normal controls (NC) matched for age and sex using voxel-based morphometry on T1-3T-MRI. We found decreased GMD in the anterior cingulate-temporal gyri and increased GMD in the posterior cingulate gyrus in SZ relative to NC. WMD reduction was found in the inferior frontal and posterior parietal regions in SZ relative to NC. GMD in the insula/caudate correlated with PS, while GMD in the middle frontal gyrus and cerebellum correlated with NS. WMD in the middle frontal and superior frontal regions correlated with PS and NS respectively. Invers correlations were found between GMD in the parietal lobe and the uvula with PS. An inverse correlation was found between GMD in the cerebellum and NS. Inverse correlation was also found in the WMD of the occipital region and superior frontal regions with PS and NS respectively. Comparison between male groups revealed decreased total GMD in male patients, while no differences were observed between female groups. These correlational findings suggest that symptom profiles in schizophrenia show unique GM/WM phenotypes.

show abstract

Section: Structural Findingsmentioning

confidence: 71%

Sex differences and symptom based gray and white matter densities in schizophrenia

Marïë¹

2022

Cortica

View full text Add to dashboard Cite

show abstract

“…To date, functional imaging studies have not consistently found associations between negative symptoms and reduced prefrontal activation during executive (and non-executive) task performance [for a review see Goghari, Sponheim, & MacDonald ( 2010 )]. Recently, however, our group found support for reduced activation in parts of the lateral prefrontal cortex in patients with negative symptoms compared to those without, in a study using a novel paradigm putatively more closely linked to negative symptoms than standard executive tasks (Fuentes-Claramonte et al, 2022 ).…”

Section: Discussionmentioning

confidence: 82%

Do the negative symptoms of schizophrenia reflect reduced responsiveness to reward? Examination using a reward prediction error (RPE) task

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background A leading theory of the negative symptoms of schizophrenia is that they reflect reduced responsiveness to rewarding stimuli. This proposal has been linked to abnormal (reduced) dopamine function in the disorder, because phasic release of dopamine is known to code for reward prediction error (RPE). Nevertheless, few functional imaging studies have examined if patients with negative symptoms show reduced RPE-associated activations. Methods Matched groups of DSM-5 schizophrenia patients with high negative symptom scores (HNS, N = 27) or absent negative symptoms (ANS, N = 27) and healthy controls (HC, N = 30) underwent fMRI scanning while they performed a probabilistic monetary reward task designed to generate a measure of RPE. Results In the HC, whole-brain analysis revealed that RPE was positively associated with activation in the ventral striatum, the putamen, and areas of the lateral prefrontal cortex and orbitofrontal cortex, among other regions. Group comparison revealed no activation differences between the healthy controls and the ANS patients. However, compared to the ANS patients, the HNS patients showed regions of significantly reduced activation in the left ventrolateral and dorsolateral prefrontal cortex, and in the right lingual and fusiform gyrus. HNS and ANS patients showed no activation differences in ventral striatal or midbrain regions-of-interest (ROIs), but the HNS patients showed reduced activation in a left orbitofrontal cortex ROI. Conclusions The findings do not suggest that a generalized reduction of RPE signalling underlies negative symptoms. Instead, they point to a more circumscribed dysfunction in the lateral frontal and possibly the orbitofrontal cortex.

show abstract

“…Since physicians may not provide the optimal choice in the efficacy and safety of antipsychotics according to their expertise or evaluation results, precise individualized medication is necessary for improving social function and activities of daily living 28,29 . The PANSS scale is a clinically established tool for assessing mental functioning, encompassing positive and negative symptom dimensions.…”

Section: Discussionmentioning

confidence: 99%

The effectiveness of personalized medication based on drug-related genes, for schizophre-nia patients with resistance to traditional drugs.

Zhou,

Zhang,

Wang

et al. 2024

Investigación Clínica

View full text Add to dashboard Cite

We aimed to study the impact of personalized medication based on drug-related genes for schizophrenia patients with resistance to traditional drugs. One hundred and ten schizophrenia patients who sought treatment at our medical facility between June 2021 and February 2023 were chosen and divided at random into two groups: one group (n=55) received conventional medication, while the other group (n=55) received personalized medication based on their genetic profile. The study compared the levels of inflammatory cytokines and neurotrophic factors, as well as the scores on the Positive and Negative Symptoms Scale (PANSS), Brief Psychiatry Rating Scale (BPRS), So-cial Skills Psychometric Instruments (SSPI), and Ability of Daily Living Scale (ADL) between the two groups. Following the treatment, both groups exhibited reduced levels of TNF-α and IL -1β compared to pre-treatment levels, with the gene-guided group showing even lower levels (p<0.05). Conversely, the levels of NGF and BDNF increased in both groups post-treatment, with the gene-guided group demonstrating even higher levels (p<0.05). Additionally, the PANSS and BPRS scores decreased in both groups after treatment, with the gene-guided group showing even lower scores (p<0.05). On the other hand, both groups’ SSPI and ADL scores increased post-treatment, with the gene-guided group exhibiting higher scores (p<0.05). The overall efficacy of the treatment in the gene-guided group was superior to that in the conventionally treated group (p<0.05). Personalized medication guided by pharmacogenetics has the po-tential to enhance cognitive function, facilitate neurological recovery, improve social functioning, and enhance the daily living skills of individuals with schizo-phrenia, thereby facilitating their successful reintegration into society.

show abstract

Negative schizophrenic symptoms as prefrontal cortex dysfunction: Examination using a task measuring goal neglect

Cited by 9 publications

References 62 publications

Sex differences and symptom based gray and white matter densities in schizophrenia

Sex differences and symptom based gray and white matter densities in schizophrenia

Do the negative symptoms of schizophrenia reflect reduced responsiveness to reward? Examination using a reward prediction error (RPE) task

The effectiveness of personalized medication based on drug-related genes, for schizophre-nia patients with resistance to traditional drugs.

Contact Info

Product

Resources

About